Stephens Investment Management Group LLC Has $43.51 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Stephens Investment Management Group LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 290,354 shares of the medical device company’s stock after buying an additional 15,007 shares during the period. Stephens Investment Management Group LLC’s holdings in DexCom were worth $43,507,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of DXCM. World Asset Management Inc lifted its stake in shares of DexCom by 2.4% in the 2nd quarter. World Asset Management Inc now owns 2,982 shares of the medical device company’s stock valued at $447,000 after purchasing an additional 69 shares during the last quarter. OLD National Bancorp IN lifted its stake in shares of DexCom by 1.1% in the 2nd quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock valued at $1,474,000 after purchasing an additional 108 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of DexCom by 4.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,750 shares of the medical device company’s stock valued at $412,000 after purchasing an additional 115 shares during the last quarter. Alps Advisors Inc. lifted its stake in shares of DexCom by 3.6% in the 1st quarter. Alps Advisors Inc. now owns 3,659 shares of the medical device company’s stock valued at $436,000 after purchasing an additional 126 shares during the last quarter. Finally, Wedbush Securities Inc. lifted its stake in shares of DexCom by 4.4% in the 2nd quarter. Wedbush Securities Inc. now owns 3,108 shares of the medical device company’s stock valued at $466,000 after purchasing an additional 130 shares during the last quarter. 96.13% of the stock is owned by institutional investors.

In other news, EVP Steven Robert Pacelli sold 3,597 shares of the business’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $116.71, for a total transaction of $419,805.87. Following the transaction, the executive vice president now owns 72,570 shares in the company, valued at approximately $8,469,644.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Quentin S. Blackford sold 8,874 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $118.95, for a total transaction of $1,055,562.30. The disclosure for this sale can be found here. Insiders sold a total of 55,665 shares of company stock worth $7,344,275 in the last quarter. Insiders own 1.80% of the company’s stock.

DXCM traded up $3.37 during trading on Thursday, hitting $156.87. The stock had a trading volume of 11,286 shares, compared to its average volume of 903,495. The stock has a market capitalization of $14.00 billion, a price-to-earnings ratio of 521.66 and a beta of 0.80. DexCom, Inc. has a 12 month low of $105.05 and a 12 month high of $161.30. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56. The company has a 50 day simple moving average of $150.23.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, July 31st. The medical device company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.01 by $0.07. The firm had revenue of $336.40 million for the quarter, compared to the consensus estimate of $304.40 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business’s quarterly revenue was up 38.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.10) EPS. As a group, research analysts forecast that DexCom, Inc. will post 0.97 EPS for the current year.

Several equities research analysts recently issued reports on DXCM shares. Piper Jaffray Companies lifted their price objective on shares of DexCom from $173.00 to $182.00 and gave the company a “positive” rating in a research note on Wednesday, July 31st. JPMorgan Chase & Co. lifted their price objective on shares of DexCom from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. BMO Capital Markets lifted their price objective on shares of DexCom from $167.00 to $172.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Northland Securities reaffirmed a “hold” rating and issued a $125.00 price objective on shares of DexCom in a research note on Thursday, June 6th. Finally, Raymond James lifted their price objective on shares of DexCom from $150.00 to $172.00 and gave the company an “outperform” rating in a research note on Thursday, August 1st. Six analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. DexCom currently has a consensus rating of “Buy” and an average target price of $166.75.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Return on Investment (ROI)

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.